Cancer News and Research

Latest Cancer News and Research

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.

8 Jan 2010

University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD

University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.

8 Jan 2010

National survey reveals many Canadians understand risk of colon cancer, but are not taking action

A new national survey reveals that while almost all Canadians understand the importance of getting checked for colon cancer, most have not had a screening test and are confused about how and when it should happen.

8 Jan 2010

Genzyme enters into mutual cooperation agreement with Relational Investors

Genzyme Corporation and San-Diego based institutional investor Relational Investors LLC announced today that they have entered into a mutual cooperation agreement. Relational, a $6 billion private investment fund, began investing in Genzyme shares in late 2008 and currently owns approximately 4 percent of the company’s common stock.

8 Jan 2010

Final health care reform legislation requires comprehensive coverage of smoking cessation treatment

As Congress negotiates a final health care reform bill, lawmakers should seize this unprecedented opportunity to invest in proven measures that prevent costly diseases from occurring in the first place, which will improve health and reduce health care costs. These include measures to prevent and reduce tobacco use, which remains the leading cause of preventable death in the United States, killing more than 400,000 people and costing the nation $96 billion in health care expenditures annually.

8 Jan 2010

Gene modification of human embryonic stem cells may yield potential treatments for genetic diseases

Biologists have developed an efficient way to genetically modify human embryonic stem cells. Their approach, which uses bacterial artificial chromosomes to swap in defective copies of genes, will make possible the rapid development of stem cell lines that can both serve as models for human genetic diseases and as testbeds on which to screen potential treatments, they say.

8 Jan 2010

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Researchers at the Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University in Montreal have discovered a previously unsuspected link between two different genetic pathways which suppress the growth of cancer tumours.

8 Jan 2010

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma.

8 Jan 2010

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Reata Pharmaceuticals, Inc. (Reata) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced today that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata’s lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets.

8 Jan 2010

Springer signs agreement with ISOBM to co-publish the journal Tumor Biology

Springer, a leading publisher in the fields of science, technology and medicine, has signed an agreement with the International Society of Oncology and BioMarkers (ISOBM) to co-publish the journal Tumor Biology starting in January 2010.

8 Jan 2010

Biovest International receives Orphan Drug Designation for its personalized lymphoma vaccine

Biovest International, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized lymphoma vaccine. BiovaxID represents a new class of active immunotherapy and is one of the few select late-stage patient-specific cancer vaccines vying to be among the first to reach market.

8 Jan 2010

Epigenetic diagnosis and therapies, a new strategy for treating cancer

A tumor's genetic profile is often useful when diagnosing and deciding on treatment for certain cancers, but inexplicably, genetically similar leukemias in different patients do not always respond well to the same therapy.

7 Jan 2010

UAB issues updated guidelines for childhood and teen immunization schedule

The co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases is a member of the committee that this week issued updated guidelines for childhood and teen immunizations to include formal recommendations that children older than 6 months get the H1N1 influenza vaccine to guard against swine flu, and that combination vaccines are generally preferred over separate injections.

7 Jan 2010

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer.

7 Jan 2010

OncoDiagnostic Laboratory acquired by Predictive Biosciences

Predictive Biosciences today announced that it has acquired Cleveland, Ohio based OncoDiagnostic Laboratory (“ODL”), a private, Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians nationwide.

7 Jan 2010

Sales figures for Abstral presented in a press release in Europe

Orexo AB announces today that its partner ProStrakan Group plc has presented its sales figures for Abstral in Europe in a press release. ProStrakan states that sales of Abstral underwent a strong development in 2009 and sales in the range of GBP 5 M – GBP 6 M were achieved for full-year.

7 Jan 2010

Webinar features recent updates on meaningful use of certified EHR systems

Community oncologists, practice administrators and clinical staff interested in learning how the American Recovery and Reinvestment Act (ARRA), otherwise known as the stimulus package, can affect health care IT plans for community-based oncology practices are invited to attend a free webinar at 2 p.m. EST (11 a.m. PST) on Friday, Jan. 15, 2010. To register, visit www.MyOncologyServices.com/HIT. Registration is free, but space is limited.

From Elekta 7 Jan 2010

Cancer treatment-related toxicities have negative effect on quality of life, survivors' perspective

In a first-ever initiative, renowned health-care providers identify and describe how cancer treatment-related toxicities have a negative effect on quality of life from the perspective of patients and survivors.

7 Jan 2010

Educational sessions and special workshops highlight advancements in molecular imaging

SNM's Conjoint Mid-Winter Meetings, Jan. 27-Feb. 2, 2010, in Albuquerque, N.M., will bring together four scientific meetings under one umbrella. The meeting, which provides attendees with the opportunity to earn up to 25 continuing education credits, will highlight the latest advancements in molecular imaging and nuclear medicine. The educational sessions will conclude with special workshops on nanomedicine and clinical trials.

7 Jan 2010

Interactive Data to serve as MFAC's Foundation Partner for 2010

Mutual Funds Against Cancer (MFAC), one of the leading advocates in the fight against cancer within the mutual fund and financial services industries, today announced that Interactive Data Corporation (NYSE: IDC), a leading provider of financial market data, analytics and related solutions, will serve as its Foundation Partner for 2010.

7 Jan 2010

Cancer News and Research

Latest Cancer News and Research

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD

National survey reveals many Canadians understand risk of colon cancer, but are not taking action

Genzyme enters into mutual cooperation agreement with Relational Investors

Final health care reform legislation requires comprehensive coverage of smoking cessation treatment

Gene modification of human embryonic stem cells may yield potential treatments for genetic diseases

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Springer signs agreement with ISOBM to co-publish the journal Tumor Biology

Biovest International receives Orphan Drug Designation for its personalized lymphoma vaccine

Epigenetic diagnosis and therapies, a new strategy for treating cancer

UAB issues updated guidelines for childhood and teen immunization schedule

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

OncoDiagnostic Laboratory acquired by Predictive Biosciences

Sales figures for Abstral presented in a press release in Europe

Webinar features recent updates on meaningful use of certified EHR systems

Cancer treatment-related toxicities have negative effect on quality of life, survivors' perspective

Educational sessions and special workshops highlight advancements in molecular imaging

Interactive Data to serve as MFAC's Foundation Partner for 2010

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Newsletters you may be interested in